Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Infinity Pharmaceuti (INFI) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview as of [[ item.timeDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 71,110
  • Shares Outstanding, K 49,450
  • Annual Sales, $ 109,070 K
  • Annual Income, $ -128,380 K
  • 36-Month Beta 2.21
  • Price/Sales 0.65
  • Price/Book 0.69

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.94 +51.60%
on 11/08/16
1.65 -13.64%
on 12/06/16
+0.46 (+48.44%)
since 11/07/16
3-Month
0.84 +69.64%
on 11/04/16
1.77 -19.49%
on 09/27/16
-0.06 (-3.72%)
since 09/07/16
52-Week
0.84 +69.64%
on 11/04/16
8.16 -82.54%
on 01/04/16
-6.19 (-81.30%)
since 12/07/15

Most Recent Stories

More News
VIVUS (VVUS) Reports Narrower-than-Expected Loss in Q3

VIVUS (VVUS) reported a loss of 9 cents per share in the third quarter of 2016, narrower than the Zacks Consensus Estimate of a loss of 25 cents.

Infinity (INFI) Reports Narrower-than-Expected Loss in Q3

Infinity Pharmaceuticals, Inc. (INFI) reported a loss of 39 cents per share in third-quarter 2016.

VIVUS (VVUS) Reports Narrower-than-Expected Loss in Q3

VIVUS (VVUS) reported a loss of 9 cents per share in the third quarter of 2016, narrower than the Zacks Consensus Estimate of a loss of 25 cents.

Endocyte (ECYT) Stock Up on Lower-than-Expected Q3 Loss

Endocyte (ECYT) reported a narrower-than-expected third-quarter 2016 loss of 21 cents per share.

Mannkind (MNKD) Q3 Earnings Beat, Inks Deal with Sanofi

MannKind Corp (MNKD) reported earnings of 26 cents per share in the third quarter of 2016.

Keryx (KERX) Q3 Loss Wider than Expected, Restores Supply

Keryx (KERX) reported third-quarter 2016 loss of 39 cents per share on revenues of $6.3 million.

Blog Coverage Bristol-Myers Squibb and Infinity Pharma Collaborate for Clinical Trials to Test Combination Drugs

LONDON, UK / ACCESSWIRE / November 10, 2016 / Active Wall St. blog coverage looks at the headline from Bristol-Myers Squibb Co. (NASDAQ: BMY) and Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) ("Infinity")as...

Catalyst (CPRX) Reports Narrower-than-Expected Loss in Q3

Catalyst Pharmaceuticals (CPRX) reported a narrower-than-expected third-quarter 2016 loss of 5 cents per share.

Mylan (MYL) Q3 Earnings & Revenues Miss on EpiPen Woes

Mylan (MYL) reported lowered-than-expected third-quarter 2016 earnings of $1.38 per share.

Celldex (CLDX) Q3 Loss Narrower than Expected, Sales Beat

Celldex (CLDX) reported third-quarter 2016 loss of 29 cents per share, narrower than the Zacks Consensus Estimate of 32 cents.

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

Infinity Pharmaceuticals, Inc. is an innovative cancer drug discovery and development company that is seeking to leverage its strength in small molecule drug technologies to discover, develop, and deliver to patients best-in-class medicines for the treatment of cancer and related conditions.

See More

Support & Resistance

2nd Resistance Point 1.83
1st Resistance Point 1.71
Last Price 1.41
1st Support Level 1.42
2nd Support Level 1.25

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.